echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Science News > Domestic innovative drugs are emerging, and local innovative drugs are selected for the first time in the plenary meeting

    Domestic innovative drugs are emerging, and local innovative drugs are selected for the first time in the plenary meeting

    • Last Update: 2021-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    From June 4th to 8th, the 57th American Society of Clinical Oncology (ASCO) Annual Meeting will be held online in the form of a virtual meeting.


    With the burst of innovation in the field of China's biomedicine, more and more Chinese companies have emerged at the ASCO conference in recent years.


    This year, 16 studies from Chinese scholars were selected as oral reports, breaking records.


    It is reported that Junshi Biotech's study selected for the plenary meeting is the phase 3 clinical JUPITER-02 study (NCT03581786) of teriprizumab combined with gemcitabine and cisplatin in the first-line treatment of nasopharyngeal carcinoma (NCT03581786), which aims to compare teripril alone The efficacy and safety of anti-combined gemcitabine/cisplatin and placebo combined with gemcitabine/cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma.


    Picture from Junshi Bio

    A total of 289 patients with recurrent/metastatic nasopharyngeal carcinoma who had not received chemotherapy were enrolled in the study, of which 146 were in the combination chemotherapy group with teriprizumab (240 mg, Q3W) and 143 were in the combination chemotherapy group with placebo.


    As of the interim analysis date of May 30, 2020, the median treatment duration in decibels for the teriprizumab group and the placebo group was 39 weeks and 36 weeks.


    In addition to Junshi's breakthrough research on nasopharyngeal carcinoma, Chinese scholars also brought advances in the treatment of other diseases during the ASCO period.


    In terms of breast cancer treatment, a total of 3 studies from Chinese scholars were selected for oral reports, and 2 were from Hengrui Medicine.


      In the treatment of esophageal cancer, the popularity of neoadjuvant immunotherapy continues.


      In the field of hematology and tumors, the global phase I clinical research results of the Bcl-2 inhibitor lisaftoclax (APG-2575) brought by Ascent Pharmaceuticals show that APG-2575 treats relapsed/refractory (R/R) chronic lymphocytic leukemia/small The objective response rate (ORR) of patients with lymphocytic lymphoma (CLL/SLL) reached 85.


      In terms of melanoma, the new small molecule MDM2 inhibitor alrizomadlin (APG-115) of Ascent Pharmaceuticals has brought ORR in a phase 2 clinical study in combination with pembrolizumab to combat unresectable/metastatic melanoma patients who have failed immuno-oncology drug treatment.


      Cancer was once regarded as a terminal illness, and with the development of modern medicine, more and more treatment options have brought new options for patients to extend their lives.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.